March 18, 2025 04:15 AM EDTUpdated 06:15 AM

Sofinnova Partners lands €165M, backed by big pharma, to build early-stage biotechs in Europe

Kyle LaHucik

Biotech Correspondent

European life sciences investor Sofinnova Partners disclosed a €165 million acceleration fund on Tuesday to back early-stage science in Italy, France, the United Kingdom and …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

Sofinnova Partners lands €165M, backed by big pharma, to build early-stage biotechs in Europe

Kyle LaHucik

Biotech Correspondent

Sign up to read this article for free.

‭ Regulatory Lead / Head of Regulatory‬

Autonomy Bio Inc.

San Francisco, CA 94107, USA

Trump asks 'very tough hombre' Dr. Oz to lead MFN talks

US warns drugmakers against misrepresenting cost of imported products

Endpoints 100 biotech survey: Welcome to the summer of biotech’s discontent

About 5% of CBER and CDER left after FDA staff cuts, analysis finds

Big leases, bigger regrets: Biotech slump turns swanky offices from asset into liability

Does your supply chain hold up under pressure for high-risk temperature-critical shipments?

Sofinno­va Part­ners lands €165M, backed by big phar­ma, to build ear­ly-stage biotechs in Eu­rope

Biotech Correspondent

Sign up to read this article for free.

Autonomy Bio Inc.

San Francisco, CA 94107, USA

Sofinnova Partners lands €165M, backed by big pharma, to build early-stage biotechs in Europe